(Q36205403)

12 August 2017

Eribulin mesylate in patients with refractory cancers: a Phase I study (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

Toru Mukohara

1

1 reference

12 August 2017

Shunji Nagai

2

1 reference

12 August 2017

Hirofumi Mukai

3

1 reference

12 August 2017

Masayuki Namiki

4

1 reference

12 August 2017

Hironobu Minami

5

1 reference

12 August 2017

language of work or name

1 reference

2 September 2011

1 reference

Investigational New Drugs

12 August 2017

1 reference

12 August 2017

30

1 reference

12 August 2017

5

1 reference

12 August 2017

1926-1933

1 reference

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

Management of toxicities associated with the administration of taxanes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432792

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

1 October 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9741-2

[Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21887501

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9741-2

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

21887501

1 reference